BIOMAT Database Logo BIOMAT Database Logo

Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. 2008

Dan J Stein, and David S Baldwin, and Francesca Baldinetti, and Francine Mandel
Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa. djs2@sun.ac.za

Epidemiological evidence supports comorbidity of generalized anxiety disorder (GAD) and major depressive disorder (MDD) or dysthymia, and its association with significant disability. As pregabalin, a new alpha(2)-delta anxiolytic treatment for GAD, unlike most other licensed treatments for GAD has not undergone investigation in patients with MDD, we examined its efficacy in depressive symptoms associated with GAD, through a post-hoc analysis of the existing clinical trial database. The results provide consistent evidence that in patients with GAD pregabalin reduced associated symptoms of depression. This was seen in the 150 mg/day, 300-450 mg/day and 600 mg/day dosing groups. Even in subjects with more prominent depressive symptoms, pregabalin remained effective for both sub-syndromal depression and GAD symptoms, with pregabalin 300-450 mg/day demonstrating the most beneficial response. In conclusion, pregabalin, an alternative treatment option for GAD with a novel mechanism of action, also demonstrated efficacy in treating depressive symptoms typically encountered in GAD patients.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003863 Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders. Depressive Symptoms,Emotional Depression,Depression, Emotional,Depressive Symptom,Symptom, Depressive
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D005680 gamma-Aminobutyric Acid The most common inhibitory neurotransmitter in the central nervous system. 4-Aminobutyric Acid,GABA,4-Aminobutanoic Acid,Aminalon,Aminalone,Gammalon,Lithium GABA,gamma-Aminobutyric Acid, Calcium Salt (2:1),gamma-Aminobutyric Acid, Hydrochloride,gamma-Aminobutyric Acid, Monolithium Salt,gamma-Aminobutyric Acid, Monosodium Salt,gamma-Aminobutyric Acid, Zinc Salt (2:1),4 Aminobutanoic Acid,4 Aminobutyric Acid,Acid, Hydrochloride gamma-Aminobutyric,GABA, Lithium,Hydrochloride gamma-Aminobutyric Acid,gamma Aminobutyric Acid,gamma Aminobutyric Acid, Hydrochloride,gamma Aminobutyric Acid, Monolithium Salt,gamma Aminobutyric Acid, Monosodium Salt
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069583 Pregabalin A gamma-aminobutyric acid (GABA) derivative that functions as a CALCIUM CHANNEL BLOCKER and is used as an ANTICONVULSANT as well as an ANTI-ANXIETY AGENT. It is also used as an ANALGESIC in the treatment of NEUROPATHIC PAIN and FIBROMYALGIA. (R-)-3-isobutyl GABA,(S)-3-(aminomethyl)-5-methylhexanoic acid,(S+)-3-isobutyl GABA,3-(aminomethyl)-5-methylhexanoic acid,3-isobutyl GABA,CI 1008,CI-1008,Lyrica,1008, CI,3 isobutyl GABA,CI1008,GABA, 3-isobutyl

Related Publications

Dan J Stein, and David S Baldwin, and Francesca Baldinetti, and Francine Mandel
Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms.
July 1996, The Journal of clinical psychiatry,
Dan J Stein, and David S Baldwin, and Francesca Baldinetti, and Francine Mandel
Long-term efficacy of pregabalin in generalized anxiety disorder.
January 2008, International clinical psychopharmacology,
Dan J Stein, and David S Baldwin, and Francesca Baldinetti, and Francine Mandel
Pooled analysis of venlafaxine XR efficacy on somatic and psychic symptoms of anxiety in patients with generalized anxiety disorder.
January 2004, Depression and anxiety,
Dan J Stein, and David S Baldwin, and Francesca Baldinetti, and Francine Mandel
Etizolam in the treatment of generalized anxiety disorder associated with depressive symptoms.
January 1989, Current medical research and opinion,
Dan J Stein, and David S Baldwin, and Francesca Baldinetti, and Francine Mandel
Dose-response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trials.
July 2007, Pharmacopsychiatry,
Dan J Stein, and David S Baldwin, and Francesca Baldinetti, and Francine Mandel
A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder.
September 2011, Canadian journal of psychiatry. Revue canadienne de psychiatrie,
Dan J Stein, and David S Baldwin, and Francesca Baldinetti, and Francine Mandel
[Generalized anxiety disorder with comorbidity. Treatment with pregabalin].
November 2006, Der Nervenarzt,
Dan J Stein, and David S Baldwin, and Francesca Baldinetti, and Francine Mandel
Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder.
March 2010, The international journal of neuropsychopharmacology,
Dan J Stein, and David S Baldwin, and Francesca Baldinetti, and Francine Mandel
Characterizing sexual function in patients with generalized anxiety disorder: a pooled analysis of three vilazodone studies.
January 2016, Neuropsychiatric disease and treatment,
Dan J Stein, and David S Baldwin, and Francesca Baldinetti, and Francine Mandel
Pregabalin for the treatment of patients with generalized anxiety disorder with inadequate treatment response to antidepressants and severe depressive symptoms.
September 2015, International clinical psychopharmacology,
Copied contents to your clipboard!